Anticoagulation after primary PCI does not prevent adverse outcomes in STEMI patients

Anticoagulation after primary percutaneous coronary intervention (PCI) does not prevent adverse outcomes in patients with ST-segment elevation myocardial infarction (STEMI), according to late breaking research presented in a Hot Line session today at ESC Congress 2023.

Congressional probe questions clinical trials run in China, citing Army involvement

A House committee is investigating whether brand drug companies are collaborating with the Chinese military when they run clinical trials in that country. “For over

August 20, 2024

Almost 40 years after an adcomm’s warning: FDA and sponsors withdraw approval for anabolic steroid

The FDA announced that it’s withdrawing the approval of Gemini Laboratories’ anabolic steroid Oxandrin (oxandrolone) and four generic versions, a decades-old treatment once indicated for

June 28, 2023

Outcomes in Resected Melanoma Influenced by Timing of Recurrence

Early recurrence after adjuvant anti-PD-1/L1 therapy for melanoma portended shorter survival, and these patients benefited more from non-PD-1-targeted systemic therapies, a subgroup analysis of a

August 9, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.